2645-P: Changes in Eating Behavior Before and After Semaglutide Administration in People with Obesity

Introduction and Objective: Semaglutide suppresses appetite and induces dose-dependent weight reduction; however, the association between changes in eating behavior and weight reduction remains unclear. We investigated changes in eating behavior before and after 6 months of semaglutide treatment and their association with body composition in people with obesity. Methods: We studied 25 patients with obesity treated with semaglutide (8 men, 17 women; median age, 47 years). Body weight, body composition (TANITA body composition analyzer), and eating behavior were assessed at baseline and after 6 months. Patients were stratified into two groups according to weight loss: ≥10% weight loss (Group A, n=8) and <10% weight loss (Group B, n=17). Eating behavior was evaluated using the 55-item questionnaire of the Japan Society for the Study of Obesity (2022). Differences from reference values in non-obese individuals were calculated, and changes over the 6-month period were defined as improvement scores for group comparisons. Results: BMI decreased from 39.2 kg/m² (29.9-70.6) at baseline to 36.7 kg/m² (24.8-68.8) after 6 months. Percentage changes were −8.2% (−0.9 to −17.7) for body weight, −14.9% (−2.3 to −30.2) for body fat mass, and −2.2% (−11.2 to +8.2) for muscle mass. In the Eating Behavior Questionnaire, the magnitude of improvement was significantly greater in Group A than in Group B for the following domains: perception of constitution and body weight (−25.0 vs. −8.0%, p = 0.028), Eating motivation (−39.5 vs. −7.0%, p = 0.047), food preference (−37.5 vs. −9.0%, p = 0.014), and regularity of eating habits (−23.5 vs. 0.0 %, p = 0.022). No significant differences were observed in substitute eating, sense of hunger and satiety, or eating style. Conclusion: In conclusion, weight loss exceeding 10% over 6 months was associated with significant improvements in multiple eating behavior domains. Disclosure M. Hitomi: None. A. Suzuki: None. H. Kubo: None. H. Shimotatara: None. R. Ichikawa: None. N. Kikuchi: None. N. Hiki: None. T. Miyatsuka: Advisory Panel; Current; Eli Lilly and Company. Speaker's Bureau; Current; Eli Lilly and Company. Advisory Panel; Current; Novo Nordisk. Speaker's Bureau; Current; Novo Nordisk, Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma, Tanabe Pharma.